← Leaderboards
Stephen R Wisniewski
University Of Pittsburgh At Pittsburgh
$41,152,197
Attributed
$90,815,037
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.6M · FY2012–25$20M$15M$10M$5M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$90,815,037 · 9
By mechanism
U01$42,820,340 · 4
UM1$26,630,613 · 1
UG1$17,077,254 · 1
U24$3,100,159 · 2
R34$1,186,671 · 1
Top collaborators
- Michael J Bell7 shared
- Wendy C King7 shared
- Frank C. Sciurba6 shared
- Charles T Esmon5 shared
- Balasubramani K Goundappa5 shared
- Michael John Becich4 shared
- Naftali Kaminski4 shared
- James H. Morrissey4 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Alison Morris$31,399,077
- Wendy C King$2,599,556
- Maria Mori Brooks$44,871,550
- Karoly Mirnics$12,881,071
- Balasubramani K Goundappa$8,538,627
Others in their field
Top investigators on “Protocols Documentation”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Jeffrey P Krischer · University Of South Florida$562,015,656
- Lawrence Corey · Fred Hutchinson Cancer Center$498,533,651
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Judith S. Currier · University Of California Los Angeles$445,196,577
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$381,639,813
Research focus
Protocols DocumentationBaseDesignComplexSiteMedicalClinical TrialsPreventEnsureMorbidity - Disease RateResponsePharmaceutical PreparationsRandomizedInflammationNovel TherapeuticsMediatingLeadAdultMolecularEffectivenessFundingProgramsCommunicationClinical Research
Grant awards (42)
2/2 Percutaneous Intervention Versus Observational Trial of Arterial ductus management in Low-weight infants (PIVOTAL) Data Coordinating Center$455,895
U24 · FY2025 · HL · contact PI
2/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial$440,448
U24 · FY2025 · HL · contact PI
Clarifying the Optimal Application of SLT Therapy (COAST) Trial$7,182,740
UG1 · FY2024 · EY · contact PI
2/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial$435,822
U24 · FY2024 · HL · contact PI
2/2 Percutaneous Intervention Versus Observational Trial of Arterial ductus management in Low-weight infants (PIVOTAL) Data Coordinating Center$432,945
U24 · FY2024 · HL · contact PI
Clarifying the Optimal Application of SLT Therapy (COAST) Trial$2,769,231
UG1 · FY2023 · EY · contact PI
2/2 Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial$445,858
U24 · FY2023 · HL · contact PI
2/2 Percutaneous Intervention Versus Observational Trial of Arterial ductus management in Low-weight infants (PIVOTAL) Data Coordinating Center$442,001
U24 · FY2023 · HL · contact PI
Clarifying the Optimal Application of SLT Therapy (COAST) Trial$2,679,188
UG1 · FY2022 · EY · contact PI
2/2 Percutaneous Intervention Versus Observational Trial of Arterial ductus management in Low-weight infants (PIVOTAL) Data Coordinating Center$447,190
U24 · FY2022 · HL · contact PI
Clarifying the Optimal Application of SLT Therapy (COAST) Trial$2,657,465
UG1 · FY2021 · EY · contact PI
Clarifying the Optimal Application of SLT Therapy (COAST) Trial$1,788,630
UG1 · FY2020 · EY · contact PI
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)$4,291,369
U01 · FY2019 · HL · contact PI
Analysis and Characterization of Trauma-Induced Coagulopathy$1,777,848
UM1 · FY2019 · HL
Analysis and Characterization of Trauma-Induced Coagulopathy$4,800,000
UM1 · FY2018 · HL
Vitamin D to Prevent Severe Asthma Exacerbations in High-Risk Children: DCC$286,690
U01 · FY2018 · HL · contact PI
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)$1
U01 · FY2018 · HL · contact PI
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)$3,785,748
U01 · FY2017 · HL · contact PI
Multiple Medical Therapies for Pediatric TBI; Comparative Effectiveness Approach$2,188,923
U01 · FY2017 · NS
Analysis and Characterization of Trauma-Induced Coagulopathy$1,251,165
UM1 · FY2017 · HL
Vitamin D to Prevent Severe Asthma Exacerbations in High-Risk Children: DCC$370,621
U01 · FY2017 · HL · contact PI
Analysis and Characterization of Trauma-Induced Coagulopathy$4,800,000
UM1 · FY2016 · HL
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)$4,297,492
U01 · FY2016 · HL · contact PI
Multiple Medical Therapies for Pediatric TBI; Comparative Effectiveness Approach$3,549,523
U01 · FY2016 · NS
Vitamin D to Prevent Severe Asthma Exacerbations in High-Risk Children: DCC$374,462
U01 · FY2016 · HL · contact PI
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)$248,401
U01 · FY2016 · HL · contact PI
Multiple Medical Therapies for Pediatric TBI; Comparative Effectiveness Approach$138,121
U01 · FY2016 · NS
Analysis and Characterization of Trauma-Induced Coagulopathy$4,728,000
UM1 · FY2015 · HL
Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC)$4,397,302
U01 · FY2015 · HL · contact PI
Multiple Medical Therapies for Pediatric TBI; Comparative Effectiveness Approach$3,597,707
U01 · FY2015 · NS
Sarcoidosis and A1AT Genomics & Informatics Center$2,447,769
U01 · FY2015 · HL · contact PI
Vitamin D to Prevent Severe Asthma Exacerbations in High-Risk Children: DCC$382,192
U01 · FY2015 · HL · contact PI
Multiple Medical Therapies for Pediatric TBI; Comparative Effectiveness Approach$9,240
U01 · FY2015 · NS
Analysis and Characterization of Trauma-Induced Coagulopathy$4,704,000
UM1 · FY2014 · HL
Multiple Medical Therapies for Pediatric TBI; Comparative Effectiveness Approach$3,481,828
U01 · FY2014 · NS
Sarcoidosis and A1AT Genomics & Informatics Center$390,000
U01 · FY2014 · HL · contact PI
Analysis and Characterization of Trauma-Induced Coagulopathy$4,569,600
UM1 · FY2013 · HL
Sarcoidosis and A1AT Genomics & Informatics Center$3,628,231
U01 · FY2013 · HL · contact PI
Multiple Medical Therapies for Pediatric TBI; Comparative Effectiveness Approach$2,886,333
U01 · FY2013 · NS
Statins for Pulmonary and Cardiac Complications of Chronic HIV (The SPARC Trial)$563,422
R34 · FY2013 · HL
Sarcoidosis and A1AT Genomics & Informatics Center$2,068,387
U01 · FY2012 · HL
Statins for Pulmonary and Cardiac Complications of Chronic HIV (The SPARC Trial)$623,249
R34 · FY2012 · HL